Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-53

And just like that, Imugene becomes a CAR-T company too.....

I'm not surprised. It always made sense to do something like this, to give them both sides of the OnCARlytics technology. I expected it to be a CAR-T out of the CoH Priceman Lab, but this one looks very good, and hey - maybe they will take on something from CoH at some point as well.

I think the inclusion of a lease to a GMP manufacturing facility, and the staff to run it, is a major reason why they have gone with this deal.

Personally, I think this news says CONFIDENT in very large flashing letters. It all says AMBITIOUS. I think their future plans for IMU are much larger than they have been saying.

My mood just improved - substantially.

Cheers

Dave